Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004049 · ClinicalTrials.gov registry record · Phase 1
SR-45023A in Treating Patients With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00004049 is a Phase 1 study that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 36 participants.
The verdict
NCT00004049, a Phase 1 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of SR-45023A in treating patients who have locally advanced or metastatic solid tumors that have not responded to previous treatment.
Interventions
- DRUG apomine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 1999-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004049
The ClinicalTrials.gov registry entry for NCT00004049 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which apomine is the first listed.
NCT00004049 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004049 about?
NCT00004049 is a clinical study titled "SR-45023A in Treating Patients With Locally Advanced or Metastatic Solid Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of SR-45023A in treating patients who have locally advanced or metastatic solid tumors that have not responded to previous treatm...
What is the current status of trial NCT00004049?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 1999-04.
What interventions are being tested in trial NCT00004049?
The interventions under investigation include: apomine (DRUG).
Who is sponsoring clinical trial NCT00004049?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.